Eloquest Healthcare ReliaTect Post-Op dressings will be introduced
at the AORN Global Surgical Conference & Expo in Boston, MA
FERNDALE, Mich. -- (Business Wire)
A line of transparent post-operative dressings designed to enhance
patient care will be jointly introduced by Eloquest Healthcare®,
Inc. and Vancive Medical Technologies™, an Avery Dennison (NYSE:AVY)
business at AORN in Boston, MA. The device just received 510(k)
clearance from the FDA.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20170330006009/en/
The new dressings, called ReliaTect™, incorporate BeneHold™ CHG, an
innovative adhesive technology from Vancive Medical Technologies, that
comfortably secures the dressing to the skin, absorbs fluids and
protects the site from external contaminants. The CHG contained within
the adhesive preserves the dressings from microbial growth, making them
ideally suited for post-operative sites. Eloquest Healthcare is the
exclusive distributor of the dressings in the United States and Canada.
“The unique characteristics of the ReliaTect post-operative dressings
make them a great complement to our growing portfolio and increases the
value we are able to provide to our customers,” said Tim O’Halla,
President and CEO for Eloquest Healthcare. “The BeneHold CHG adhesive
technology delivers the combination of fluid management and sustained
transparency with antimicrobial effect of chlorhexidine gluconate,
offering clinicians a simple and innovative solution for post-op site
management.”
The ReliaTect dressings will be available in two sizes (small and large)
and designed to be ideal for various post-operative sites.
“BeneHold CHG adhesive technology adds value to post-operative
dressings,” said Kirsten Newquist, general manager for Vancive Medical
Technologies. “The collaboration with Eloquest Healthcare brings
together complementary resources, experience and expertise from each
company. We look forward to working with Eloquest Healthcare to bring
ReliaTect to market.”
Eloquest Healthcare and Vancive Medical Technologies will showcase the
new Eloquest Healthcare ReliaTect dressings in booth #3019 at the AORN
Global Surgical Conference & Expo, April 2—4 in Boston, MA. To learn
more about the Eloquest Healthcare ReliaTect post-operative dressings
with CHG, visit http://www2.eloquesthealthcare.com/ReliaTectLaunch.
About Eloquest Healthcare
Eloquest Healthcare, Inc. is a wholly owned subsidiary of Ferndale
Pharma Group, Inc. that is focused specifically on serving hospitals,
their healthcare practitioners, and patients. Eloquest Healthcare helps
deliver safer, more compassionate care by providing intuitive,
cost-effective solutions that complement treatment protocols. More
information can be found at www.eloquesthealthcare.com.
About Vancive Medical Technologies
Vancive Medical Technologies is a medical technology company with more
than three decades of expertise in adhesive chemistries and material
technologies for medical applications using pressure sensitive
adhesives. The company's applications and technologies are an integral
part of products that are in daily use in medical facilities throughout
the world. Through long-term relationships with original equipment
manufacturers, industry-specific converters and leading universities,
Vancive Medical Technologies continually finds new ways to develop
products that can improve patient care. Vancive Medical Technologies is
an Avery Dennison business headquartered in Chicago, Illinois. To learn
more about Vancive Medical Technologies, visit www.vancive.averydennison.com.
About Avery Dennison
Avery Dennison (NYSE:AVY) is a global leader in pressure-sensitive and
functional materials and labeling solutions for the retail apparel
market. The company’s applications and technologies are an integral part
of products used in every major industry. With operations in more than
50 countries and more than 25,000 employees worldwide, Avery Dennison
serves customers in the consumer packaging, graphical display,
logistics, apparel, industrial and healthcare industries. Headquartered
in Glendale, California, the company reported sales of $6.1 billion in
2016. Learn more at www.averydennison.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170330006009/en/
Contacts:
Eloquest Healthcare Contacts:
Matthew Stahl
Clinical Marketing
& Brand Director
248.586.8428
mstahl@eloquesthealthcare.com
or
Vancive
Contacts:
Andrew Deckert
Global Marketing Communications
Manager
+1 224 374 2109
andrew.deckert@averydennison.com
or
Barbara
Van Rymenam
Global Director, CHG Program
+32 (0)497 103233
barbara.van.rymenam@eu.averydennison.com
Source: Vancive Medical Technologies
© 2024 Canjex Publishing Ltd. All rights reserved.